Types of Testosterone Therapy and their Effects on the Voices of Transgender Singers

2021 ◽  
Vol 78 (3) ◽  
pp. 327-336
Author(s):  
Tessa Romano
Keyword(s):  
Hormone Therapy ◽  
Gender Dysphoria ◽  
Testosterone Therapy ◽  
Voice Teachers ◽  
Vocal Quality

Hormone therapy (HT) is the administration of hormones in an attempt to relieve gender dysphoria by obtaining the phenotype and vocal quality of one’s gender identi-ty. The information contained in this article is designed to help transgender singers and their voice teachers understand what to expect vocally during initial changes that occur on testosterone therapy in order to build awareness around and facilitate the accommodation of this period of rapid vocal change.

scholarly journals Resolution of Severe Anorexia Nervosa Associated with Gender Dysphoria (Dysphorexia) by Testosterone Therapy in Two Male Transgender Youth

2021 ◽  
Vol 1 (1) ◽  
Author(s):  
Francisco Javier Martinez Martin
Keyword(s):  
Anorexia Nervosa ◽  
Eating Disorder ◽  
Hormone Therapy ◽  
Gender Dysphoria ◽  
Pubertal Development ◽  
Parental Consent ◽  
Testosterone Therapy ◽  
Transgender Youth ◽  
Limited Success ◽  
Pubertal Transition

Anorexia nervosa is a severe and potentially lethal eating disorder. In transgender youth with severe gender dysphoria, a severe eating disorder (proposed name: dysphorexia), coherent with anorexia nervosa may be triggered by the desire to avoid the cisgender pubertal transition. In these patients, gender-affirming hormone therapy can be extremely effective. We report hereby the cases of two female-to-male transsexual patients with severe gender dysphoria whose anorexia nervosa was related to their pubertal development and who promptly recovered when they started gender-affirming hormone therapy with testosterone, after very limited success with standard psychotherapy and pharmacotherapy for anorexia nervosa. Our patients could not access pubertal suppression due to lack of parental consent in one case and failure to express the conflict in the other. We postulate that avoiding the cisgender pubertal transition with GnRH agonist treatment might also be able to prevent the development of dysphorexia.

scholarly journals Physical and Sociodemographic Features Associated With Quality of Life Among Transgender Women and Men Using Gender-Affirming Hormone Therapy

2021 ◽  
Vol 12 ◽  
Author(s):  
Eliane D. Silva ◽  
Tayane M. Fighera ◽  
Roberta M. Allgayer ◽  
Maria Inês R. Lobato ◽  
Poli Mara Spritzer
Keyword(s):  
Quality Of Life ◽  
Hormone Therapy ◽  
Gender Dysphoria ◽  
Transgender Women ◽  
Breast Development ◽  
Body Hair ◽  
Trans Men ◽  
In Trans ◽  
Trans Women

Background: Gender dysphoria is defined as a feeling of distress resulting from the incongruence between the sex assigned at birth and the gender identity, lasting longer than 6 months. In individuals with gender dysphoria, gender-affirming hormone therapy (GAHT) may improve quality of life (QoL).Objectives: We aimed to assess perceived QoL, to compare QoL scores between trans women and men and to identify possible contributing factors related to GAHT in a sample of transgender women and transgender men.Methods: In this cross-sectional study, transgender women and men were recruited by availability sampling from a national transgender health service. Individuals over 18 years old with a confirmed diagnosis of gender dysphoria receiving medically prescribed GAHT for at least 6 months were consecutively included. Also included were trans men who had undergone mastectomy and trans women who had received breast augmentation surgery. Individuals who had undergone gender affirmation surgery (specifically genital surgery) or with uncontrolled clinical/psychiatric conditions at the time of the initial assessment were excluded. Sociodemographic, physical, and hormone data were collected from all participants. The WHOQOL-BREF questionnaire was used to evaluate QoL. A total of 135 transgender individuals were invited. Seventeen individuals with previous genital surgery (12.6%) and five who refused to participate (3.7%) were excluded. Therefore, 113 patients were enrolled and completed the study (60 trans women and 53 trans men).Results: QoL scores did not differ between trans women and trans men. In trans women, greater breast development and stable relationships, and higher body mass index were associated with higher QoL domain scores. In trans men, higher domain scores were found in individuals in a stable relationship, with increased body hair, engaging in physical activity, and being employed.Conclusion: Data from this study suggest that GAHT-related physical characteristics, such as breast development in trans women and increased body hair in trans men, are similar between groups, are associated with higher QoL scores, and that sociodemographic parameters may impact these associations. Healthcare providers might consider these factors when planning interventions to improve QoL in transgender individuals.

scholarly journals An Increased Presence of Male Personalities in Dissociative Identity Disorder after Initiating Testosterone Therapy

2020 ◽  
Vol 2020 ◽  
pp. 1-3
Author(s):  
Monique Mun ◽  
Mohan Gautam ◽  
Renee Maan ◽  
Bassem Krayem
Keyword(s):  
Hormone Therapy ◽  
Gender Dysphoria ◽  
Case Reports ◽  
Dissociative Identity Disorder ◽  
Sex Hormone ◽  
Dissociative Disorder ◽  
Testosterone Therapy ◽  
Dissociative Symptoms ◽  
High Prevalence

Patients with gender dysphoria (GD) report significant dissociative symptoms and are found to have a high prevalence of a dissociative disorder of any kind. When GD patients elect to undergo cross-sex hormone therapy, there is a significant reduction in dissociative symptoms. However, to the best of our knowledge, there are no known case reports that describe an alteration of personalities in dissociative identity disorder after initiating cross-sex hormone therapy. Thus, we present a case of a 20-year-old transgender male with GD, whom after initiating cross-sex hormone therapy with testosterone experienced an increased presence of his existing male personalities.

scholarly journals Physical and Sociodemographic Features Associated With Quality of Life in Transgender Individuals Using Gender-Affirming Hormone Therapy

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A794-A795
Author(s):  
Eliane Dias Da Silva ◽  
Tayane Muniz Fighera ◽  
Roberta Martins Costa Moreira Allgayer ◽  
Maria Inês Rodrigues Lobato ◽  
Poli Mara Spritzer
Keyword(s):  
Quality Of Life ◽  
Hormone Therapy ◽  
Gender Dysphoria ◽  
Transgender Women ◽  
Genital Surgery ◽  
Trans Men ◽  
Significant Difference ◽  
In Trans ◽  
Trans Women

Abstract Background: Gender dysphoria is defined as a feeling of distress resulting from the incongruence between the gender assigned at birth and the identity gender and lasting longer than 6 months. In individuals with gender dysphoria, gender-affirming hormone therapy(GAHT) may improve quality of life (QoL). Objectives: Here, we aimed to assess perceived QoL and possible contributing factors in a sample of transgender women and transgender men using GAHT. Methods: In this cross-sectional study, transgender women and men were recruited by availability sampling from a national transgender health service. Individuals over 18 years old with a confirmed diagnosis of gender dysphoria receiving medically prescribed GAHT for at least 6 months were consecutively included. Also included were trans men who had undergone mastectomy and trans women who had received breast augmentation surgery. Individuals who had undergone gender affirmation surgery (specifically genital surgery) or with uncontrolled clinical/psychiatric conditions at the time of the initial assessment were excluded. Sociodemographic, physical, and hormone data were collected from all participants. The WHOQOL-BREF questionnaire was used to evaluate QoL. A total of 135 transgender individuals were invited. Seventeen individuals with previous genital surgery (12.6%) and five who refused to participate (3.7%) were excluded. Therefore, 113 patients were enrolled in the study (60 trans women and 53 trans men). Results: There was no significant difference in QoLbetween the groups. In trans women, greater breast development and stable relationships, and higher body mass index were associated with higher QoLdomain scores. In trans men, higher domain scores were found in individuals with a stable relationship, increased body hair, physical activity practice, and being employed. Conclusion: Data from this study suggest that GAHT-related physical characteristics are associated with higher QoLscores, and that sociodemographic parameters may impact these associations. Healthcare providers might consider these factors when planning interventions to improve QoLin transgender individuals.

Menopausal hormone therapy and uterine cancer: the acceptability of the tandem

GYNECOLOGY ◽  
2018 ◽  
Vol 20 (6) ◽  
pp. 42-47
Author(s):  
O V Yakushevskaya ◽  
S V Yureneva ◽  
A E Protasova ◽  
G N Khabas ◽  
M R Dumanovskaya
Keyword(s):  
Hormone Therapy ◽  
Uterine Cancer ◽  
Menopausal Hormone Therapy ◽  
Medical Rehabilitation ◽  
Cytostatic Treatment ◽  
Systematic Analysis ◽  
Strict Adherence ◽  
Patient Profile ◽  
The Past

The aim of the work is to conduct a systematic analysis of the available research results on the possibility of using menopausal hormone therapy (MHT) in patients who successfully completed the treatment of endometrial cancer (EC). Materials and methods. The review includes data from foreign articles published in PubMed and Medline, and domestic works published on elibrary.ru over the past 40 years. Results. The results obtained allow us to consider MHT as an independent method of medical rehabilitation for women who have undergone EC. A clear patient profile should be established, allowing the use of this method, with strict adherence to health monitoring. Conclusion Patients who have successfully completed the treatment of EC require the creation of special rehabilitation conditions in the interests of maintaining health and quality of life and should be under the close attention of the doctor. Argumented approaches to the appointment of MHT in such patients will avoid complications associated with estrogen deficiency after surgery, radiation with or without systemic (cytostatic) treatment methods.

MENOPAUSAL HORMONOTHERAPY IN ONCOGYNECOLOGIC PATIENTS

2017 ◽  
Vol 63 (6) ◽  
pp. 843-854
Author(s):  
Olga Novikova ◽  
Yelena Ulrikh ◽  
V. Nosov ◽  
A. Charkhifalakyan
Keyword(s):  
Quality Of Life ◽  
Cervical Cancer ◽  
Endometrial Cancer ◽  
Hormone Replacement Therapy ◽  
Hormone Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Menopausal Hormone Therapy ◽  
Oncological Safety

There is presented the review of domestic and foreign references on the conserved oncological safety of the use of menopausal hormone therapy after treatment for endometrial cancer, cervical cancer, borderline and malignant ovarian tumors, various variants of sarcomas of the uterus, vulva and vaginal cancer. To the opinion of the authors the refusal to prescribe menopausal hormone therapy to patients with oncogynecologic diseases in the anamnesis is usually not justified, the category of patients, to whom hormone replacement therapy is contraindicated, is well described and mentioned in the text. In other cases sex hormones can be used to treat menopausal symptoms and improve the quality of life of patients.

scholarly journals Quality-of-Life and Depressive Symptoms in Postmenopausal Women After Receiving Hormone Therapy

JAMA ◽  
2002 ◽  
Vol 287 (5) ◽  
pp. 591 ◽  
Author(s):  
Mark A. Hlatky ◽  
Derek Boothroyd ◽  
Eric Vittinghoff ◽  
Penny Sharp ◽  
Mary A. Whooley ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Depressive Symptoms ◽  
Hormone Therapy ◽  
Postmenopausal Women
Sign in / Sign up

Export Citation Format

Share Document